Laninamivir - Vaxart /Daiichi Sankyo
Alternative Names: CS-8958; Inavir; LANI; Laninamivir octanoate - Vaxart /Daiichi Sankyo; Laninamivir octanoate hydrate - Vaxart /Daiichi Sankyo; R-118958Latest Information Update: 05 Nov 2023
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Vaxart
- Class Acetamides; Antivirals; Carboxylic acids; Esters; Guanidines; Pyrans; Small molecules
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
- 30 Jun 2017 Daiichi Sankyo completes a phase III trial for Influenza virus infections (In neonates, In infants, In children) in Japan (Inhalation) (JapicCTI-163398)
- 30 Jun 2017 Daiichi Sankyo completes a phase III trial for Influenza virus infections (In children, In adolescents, In adults, In the elderly) in Japan (Inhalation) (JapicCTI-163397)